Status:
COMPLETED
An Alternative Dosing Schedule of Varenicline for Smoking Cessation
Lead Sponsor:
Roswell Park Cancer Institute
Collaborating Sponsors:
Pfizer
Conditions:
Smoking Cessation
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to explore the use of an prolonged alternative dosing schedule using varenicline for smoking cessation leading to greater quit rates and higher rates of continuous abstine...
Detailed Description
This pilot study will utilize a two group randomized design. Adult smokers who are motivated to quit smoking will be randomized to one of two treatment groups. Both groups will receive brief support c...
Eligibility Criteria
Inclusion
- currently smoking at least 15 cigarettes daily
- in good health
- able to read and speak English fluently
- have a home telephone and plan to reside in Western New York for 6 months
- willing to make quit attempt
- signed informed consent
- who planned quit attempt.
Exclusion
- serious medical condition
- depression or mental health condition requiring treatment in the past year
- history of panic disorder, psychosis, bipolar disorder
- alcohol or drug abuse in the past year
- use of tobacco products other than cigarettes
- current use of other cessation pharmacotherapies
- pregnancy/planned pregnancy.
Key Trial Info
Start Date :
March 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2015
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00835900
Start Date
March 1 2009
End Date
July 1 2015
Last Update
May 30 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Roswell Park Cancer Institute
Buffalo, New York, United States, 14263